Prognosis
Global Drug Suppliers Challenge FDA as Safety Fears Rise
- Most manufacturing of drugs sold in the U.S. is done abroad
- U.S. drug supply compromised by shortages linked to quality
This article is for subscribers only.
Regulators want to reduce U.S. dependence on foreign-made pharmaceutical ingredients, as a wave of recalls has raised questions about the safety of the global drug-supply chain.
The Food and Drug Administration is encouraging drug companies to invest in new production technologies that could help return some manufacturing to U.S. shores. The U.S. is currently home to only about a quarter of global production capacity for active pharmaceutical ingredients, according to Janet Woodcock, the director of the FDA’s Center for Drug Evaluation and Research.